Black Rock Inc. Oncocyte Corp Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.2 - $0.35 $42,672 - $74,676	-213,360 Reduced 14.97%	1,212,026 $278,000
Q1 2023 May 12, 2023	BUY	$0.2 - $0.49 $1,395 - $3,419	6,978 Added 0.49%	1,425,386 $498,000
Q4 2022 Feb 13, 2023	SELL	$0.25 - $15.6 $221,730 - $13.8 Million	-886,923 Reduced 38.47%	1,418,408 $453,000
Q3 2022 Nov 14, 2022	SELL	$0.76 - $15.98 $28,952 - $608,758	-38,095 Reduced 1.63%	2,305,331 $1.68 Million
Q2 2022 Aug 12, 2022	SELL	$0.86 - $1.53 $2.23 Million - $3.96 Million	-2,590,223 Reduced 52.5%	2,343,426 $2.11 Million
Q1 2022 May 12, 2022	SELL	$1.15 - $2.25 $68,421 - $133,868	-59,497 Reduced 1.19%	4,933,649 $7.35 Million
Q4 2021 Feb 10, 2022	BUY	$2.04 - $3.59 $1.27 Million - $2.24 Million	624,410 Added 14.29%	4,993,146 $10.8 Million
Q3 2021 Nov 09, 2021	SELL	$3.53 - $5.89 $1.27 Million - $2.13 Million	-360,990 Reduced 7.63%	4,368,736 $15.6 Million
Q2 2021 Aug 11, 2021	BUY	$3.77 - $6.0 $17.8 Million - $28.4 Million	4,729,726 New	4,729,726 $27.1 Million

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $260M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.